Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal
Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...
Alumis Inc trading halted, news pending
Inc trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...
Business Insider15d
Alumis Inc trading resumes
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ALMS: Alumis NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Business Wire14d
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. is fair to Alumis ...
BioPharma Dive14d
Immune drugmakers Alumis and Acelyrin to merge
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...
H.C. Wainwright cuts Alumis stock target to $19, maintains Buy rating
H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...
Investing24d
Alumis Inc. bolsters leadership for late-stage development
SOUTH SAN FRANCISCO - Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company with a market capitalization of $367 million, announced key executive appointments today as it prepares ...